Alector, Inc. Share Price
NASDAQ: ALEC | Micro CapAlector, Inc. Stock Performance
Open $1.82 | Prev. Close $1.78 | Circuit Range N/A |
Day Range $1.75 - $2.00 | Year Range $1.09 - $3.39 | Volume 85,316 |
Average Traded $1.84 |
Alector, Inc. Share Price Today
As of 10 August 2026, Alector, Inc.'s share price is $1.77. The stock opened at $1.82, compared to its previous close of $1.78. During today's trading session, Alector, Inc.'s share price traded between $1.75 and $2.00, with an average price of $1.87. Over the past 52 weeks, the stock has recorded a high of $3.39 and a low of $1.09. In terms of performance, Alector, Inc.'s share price has declined by 27.70% over the last six months and is down 24.15% on a year-on-year basis.
Alector, Inc. Share Price Chart
Alector, Inc. Stock Fundamentals & Key Indicators
Market Cap $182.82M | PE Ratio (TTM) -1.28 | Dividend Yield N/A |
EPS (TTM) $-1.39 | Revenue (TTM) $21.05M | Return On Equity (TTM) -466.34% |
Profit Margin -679.16% | Debt to Equity 2.27 | Quarterly Earnings Growth YoY N/A |
About Alector, Inc.
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.48 | $1.78 | +17.88% |
Jul 2026 | $2.02 | $1.51 | -24.69% |
Jun 2026 | $2.13 | $2.00 | -7.60% |
May 2026 | $2.35 | $2.17 | -8.82% |
Apr 2026 | $2.20 | $2.38 | +10.70% |
Mar 2026 | $2.33 | $2.15 | -12.42% |
Feb 2026 | $1.84 | $2.46 | +29.21% |
Jan 2026 | $1.58 | $1.90 | +21.79% |
Dec 2025 | $1.28 | $1.56 | +17.29% |
Nov 2025 | $1.50 | $1.33 | -9.83% |
Oct 2025 | $2.99 | $1.48 | -50.25% |
Sep 2025 | $2.34 | $2.96 | +26.71% |
ALEC Share Price FAQs
What is Alector, Inc. share price today?
What is the 52 week high and 52 week low of Alector, Inc. stock?
What is ALEC's market capitalisation today?
What is the 5 year returns of ALEC?
What is the high & low stock price of ALEC today?
Can I buy ALEC shares in India?